TY - JOUR
T1 - Platinum and palladium nanoparticle-containing mixture, PAPLAL, does not induce palladium allergy
AU - Shibuya, Shuichi
AU - Watanabe, Kenji
AU - Tsuji, Gaku
AU - Ichihashi, Masamitsu
AU - Shimizu, Takahiko
N1 - Funding Information:
This research was supported by funds from Musashino Pharmaceutical Co. (Tokyo, Japan) and ROHTO Pharmaceutical Co. (Osaka, Japan). Funding sources were not involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article for publication. We thank Tomoko Tachibana, Yusuke Ozawa, Toshihiko Toda (Chiba University), for their valuable technical assistance.
Publisher Copyright:
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Palladium (Pd) is a common metal found in jewellery and dental appliances, but it has been shown to be likely to cause metal allergy. We previously reported that platinum (nPt) and palladium (nPd) nanoparticle-containing mixture (PAPLAL) has both superoxide dismutase and catalase activities and that the topical application of PAPLAL improved skin atrophy induced by chronic oxidative damage in an ageing mouse model. However, the safety of PAPLAL for preventing Pd allergy remains unclear. In the present study, we investigated whether or not PAPLAL induces Pd allergy. We found that PAPLAL treatment caused no skin inflammation, while nPd administration caused only slight skin inflammation compared to the palladium chloride-induced severe reaction in an experimental metal allergy model. A gene expression analysis revealed that PAPLAL treatment significantly suppressed the expression of Inf-γ, Il-1β and Tnfα genes. Even in human clinical trials using patches containing metal nanoparticles, nPd and PAPLAL failed to induce significant skin inflammation. These results suggest that mixing with nPt in PAPLAL suppresses the inflammation response of nPd. PAPLAL can be expected to be applied to various skin treatments as a safe topical substance.
AB - Palladium (Pd) is a common metal found in jewellery and dental appliances, but it has been shown to be likely to cause metal allergy. We previously reported that platinum (nPt) and palladium (nPd) nanoparticle-containing mixture (PAPLAL) has both superoxide dismutase and catalase activities and that the topical application of PAPLAL improved skin atrophy induced by chronic oxidative damage in an ageing mouse model. However, the safety of PAPLAL for preventing Pd allergy remains unclear. In the present study, we investigated whether or not PAPLAL induces Pd allergy. We found that PAPLAL treatment caused no skin inflammation, while nPd administration caused only slight skin inflammation compared to the palladium chloride-induced severe reaction in an experimental metal allergy model. A gene expression analysis revealed that PAPLAL treatment significantly suppressed the expression of Inf-γ, Il-1β and Tnfα genes. Even in human clinical trials using patches containing metal nanoparticles, nPd and PAPLAL failed to induce significant skin inflammation. These results suggest that mixing with nPt in PAPLAL suppresses the inflammation response of nPd. PAPLAL can be expected to be applied to various skin treatments as a safe topical substance.
UR - http://www.scopus.com/inward/record.url?scp=85070072009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070072009&partnerID=8YFLogxK
U2 - 10.1111/exd.13996
DO - 10.1111/exd.13996
M3 - Article
C2 - 31260134
AN - SCOPUS:85070072009
SN - 0906-6705
VL - 28
SP - 1025
EP - 1028
JO - Experimental Dermatology
JF - Experimental Dermatology
IS - 9
ER -